Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with limited-stage small cell lung cancer (cancer that hasn't spread far) and have not had any treatment for it yet.
- You have completed concurrent chemotherapy and radiation and the cancer has not gotten worse.
- You are in generally good health, able to take care of yourself (ECOG 0 or 1), and have adequate organ function (heart, lungs, liver, kidneys, and blood).
- You do not have active autoimmune disease, active infections like hepatitis B or C, or other cancers that have been treated in the last 3 years.
- You have not had prior immunotherapy or other cancer treatments for this lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation to see if it works better than chemotherapy alone for people newly diagnosed with extensive-stage small cell lung cancer.
This trial tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy and radiation for people with limited-stage small cell lung cancer. After the initial treatment, adebrelimab is continued alone to help prevent the cancer from coming back.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
This trial tests a drug called Adebrelimab as a maintenance therapy after you finish chemotherapy and radiation (given in smaller, more frequent doses) for limited-stage small cell lung cancer. The goal is to see if it helps keep the cancer from coming back.
This Phase 3 trial tests whether adding a drug called adebrelimab (SHR-1316) to standard chemotherapy before treatment leads to more successful surgery and/or radiation for limited-stage small cell lung cancer. It’s for people who have not had any prior cancer treatment and can undergo planned “curative” treatment after 4 cycles.
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Hear when a new SCLC, Limited Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.